First, apatinib has highly selective competition in the tyrosine kinase activity of VEGFR-2, the most significant receptor in tumor pathological conditions, then blocking downstream VEGF-mediated endothelial cell proliferation and inhibiting tumor angiogenesis (76). The gene discussed is VEGFA; the disease is neoplasm.